Compare SVRE & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SVRE | CLDI |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | Israel | United States |
| Employees | 35 | 29 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.4M |
| IPO Year | N/A | N/A |
| Metric | SVRE | CLDI |
|---|---|---|
| Price | $4.46 | $0.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.8K | ★ 2.0M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,793.31 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $0.16 |
| 52 Week High | $6.30 | $7.32 |
| Indicator | SVRE | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 39.97 |
| Support Level | $1.30 | $0.16 |
| Resistance Level | $4.92 | $0.20 |
| Average True Range (ATR) | 0.39 | 0.02 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 39.13 | 43.47 |
Saverone 2014 Ltd is engaged in the design, development, and commercialization of transportation and safety solutions, designed to prevent car accidents based on its patented technology of detecting, analyzing, and locating cellular phone radio frequency, or RF signals. The company is developing two product lines: the first is an In-Cabin Driver Distraction Prevention Solution (known as SaverOne system), or DDPS; and the second is an Advanced Driver-Assistance System, or ADAS, product that detects vulnerable road users, or VRUs, and provides a warning to the vehicle regarding potential collision. Geographically, Saverone generates maximum revenue from Europe and the rest from Israel.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.